[Cancer initiation as mini-evolution].
Iwasa
Yoh
Y
yiwasscb@mbox.nc.kyushu-u.ac.jp
D000970:Antineoplastic Agents / Q000627:therapeutic use; D001549:Benzamides; D002454:Cell Differentiation / Q000235:genetics; D043171:Chromosomal Instability / Q000235:genetics; D019295:Computational Biology; D004847:Epithelial Cells / Q000166:cytology; D019143:Evolution, Molecular; D016147:Genes, Tumor Suppressor; D006801:Humans; D000068877:Imatinib Mesylate; D047908:Intracellular Signaling Peptides and Proteins / Q000627:therapeutic use; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy / Q000235:genetics / Q000473:pathology; D008962:Models, Theoretical; D009154:Mutation; D009369:Neoplasms / Q000235:genetics* / Q000473:pathology*; D014411:Neoplastic Stem Cells / Q000166:cytology / Q000473:pathology; D010879:Piperazines / Q000627:therapeutic use; D011743:Pyrimidines / Q000627:therapeutic use
D000970:Antineoplastic Agents; D001549:Benzamides; D047908:Intracellular Signaling Peptides and Proteins; D010879:Piperazines; D011743:Pyrimidines; C015482:protein kinase modulator; D000068877:Imatinib Mesylate